- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07780032
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Restless Legs Syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs that disrupts sleep and quality of life. Current medical therapies often lose effectiveness over time or are associated with significant side effects. Preliminary case reports suggest that spinal cord stimulation (SCS) may improve RLS symptoms.
This single-arm feasibility study will enroll up to 15 adults with severe, treatment-refractory primary RLS. Participants will undergo baseline clinical, neuropsychological, and electrophysiological assessments followed by implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System. Follow-up evaluations will occur through 24 months post-activation. Primary outcomes focus on device and procedure safety. Secondary outcomes evaluate changes in RLS severity, patient-reported outcomes, neurophysiological biomarkers, and device utilization.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Chris Gonzalez
- Numero di telefono: 2059964318
- Email: clgonzalez@uabmc.edu
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- UAB Hospital
-
Contatto:
- Chris Gonzalez
- Numero di telefono: 2059964318
- Email: clgonzalez@uabmc.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age >18 years and older.
- Received a medical diagnosis of RLS via first screening with Cambridge Hopkins- RLS questionnaire and confirmed via Hopkins-Hening Diagnostic questionnaire.
- IRLS Scale score ≥ 21 (classified as severe) and received a determination of treatment refractory RLS or inadequate response to standard medical treatment for RLS by a sleep medicine physician.
- RLS symptoms occur ≥ 3 nights per week.
- Willing and able to comply with study procedures.
- Able to provide informed consent.
Exclusion Criteria:
- Age <18 years.
- Neuropathic pain, other than RLS on DN4 questionnaire.
- Any mental or physical limitation that would prevent completing and of the study protocols.
- Active medical implant in the body (i.e., pacemaker).
- History of prior SCS trial or implantation.
- Currently using another device to treat RLS.
- Unable or unwilling to comply with study protocols.
- Other medical conditions that would put the subject at risk as determined by the investigators.
- Pregnant, breastfeeding, or trying to become pregnant.
- Currently participating or plans to participate in any other investigational clinical evaluation during the study period that may, in the opinion of the investigators, affect RLS.
- Ferritin < 50 ng/mL (excludes iron deficiency).
- HgA1C > 7.5 (excludes unstable diabetes melilitus)
- One or more of the following diagnoses: spinal cord injury or prior spinal surgery, severe peripheral neuropathy, severe psychiatric or cognitive disorder that may interfere with study participation, history of drug or alcohol abuse within the past year, epilepsy or seizure disorder, current active or chronic infection other than common cold, malignancy within the past 5 years (not including basal cell or squamous cell skin cancer), severe movement disorder (i.e., Parkinson's disease), deep vein thrombosis, multiple sclerosis, known or suspected allergy to SCS materials.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: SCS Implant
|
Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology.
Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and Adverse Events
Lasso di tempo: Baseline through 24 months
|
Frequency, severity, and relationship of device-, stimulation-, and procedure-related adverse events.
|
Baseline through 24 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in International Restless Legs Syndrome Scale (IRLS)
Lasso di tempo: Baseline through 24 months
|
The IRLS is a validated 10-item patient-reported measure of Restless Legs Syndrome severity.
Scores range from 0 to 40, with higher scores indicating worse symptom severity.
A decrease in score from baseline indicates improvement.
|
Baseline through 24 months
|
|
Clinician Global Impression Improvement Scale (CGI-I)
Lasso di tempo: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Patient Global Impression of Improvement (PGI-I)
Lasso di tempo: Baseline through 24 months
|
The PGI-I is a patient-reported global rating of change in symptoms and overall condition following treatment.
Scores range from 1 to 7, where 1 = Very much improved and 7 = Very much worse.
Lower scores represent a better outcome and greater perceived improvement.
|
Baseline through 24 months
|
|
Suggested Immobilization Test (SIT)
Lasso di tempo: Baseline through 24 months
|
Baseline through 24 months
|
|
|
PROMIS Sleep, Pain, Anxiety, Depression, Cognition, and Health Measures
Lasso di tempo: Baseline through 24 months
|
Baseline through 24 months
|
|
|
Changes in Neurophysiological Measures of Spinal Cord Stimulation Response
Lasso di tempo: Baseline through 24 months
|
Changes in H-reflexes, somatosensory evoked potentials (SSEPs), EEG measures, and device-recorded ECAPs.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Sleep
Lasso di tempo: Baseline through 24 months
|
Questionnaire assessing perceived sleep quality and difficulty falling asleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater sleep disturbance and a worse outcome.
The T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Pain
Lasso di tempo: Baseline through 24 months
|
Questionnaire assessing the impact of pain on daily activities and sleep during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater pain interference and a worse outcome.
The T-score range is approximately 30 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Anxiety
Lasso di tempo: Baseline through 24 months
|
Questionnaire assessing fear, anxious mood, and anxiety-related symptoms during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater anxiety and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Depression
Lasso di tempo: Baseline through 24 months
|
Questionnaire assessing depressive symptoms, negative mood, and diminished self-worth during the previous 7 days.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate greater depressive symptom burden and a worse outcome.
The T-score range is approximately 40 to 85.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Cognition
Lasso di tempo: Baseline through 24 months
|
Questionnaire assessing perceived cognitive abilities including memory, concentration, and mental acuity.
Responses are converted to PROMIS standardized T-scores .
Higher scores indicate better cognitive functioning and a better outcome.
The T-score range is approximately 20 to 80.
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Mental health battery
Lasso di tempo: Baseline through 24 months
|
Assesses overall mental health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
|
Patient-Reported Outcomes Measurement Information System - Physical Health Battery
Lasso di tempo: Baseline through 24 months
|
Assesses Overall Physical Health.
Responses are converted to PROMIS standardized T-scores.
Higher scores indicate better overall health status and a better outcome.
T-score range is approximately 20 to 80
|
Baseline through 24 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Marshall Holland, MD, University of Alabama at Birmingham
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IRB-300013464
- 1UG3NS145980-01 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .